G2B BioSolutions ApS: Financial statements 2024
CVR: 42437069
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
G2B BioSolutions ApS (CVR 42437069) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 435,674 and a net result of DKK 370,740 compared with DKK -1,513,784 the year before. Equity in the 2024 report amounted to DKK -1,350,236. The company had 1 employee in the financial year.
- Gross Profit
- DKK 435,674
- Profit/Loss
- DKK 370,740
- Equity
- DKK -1,350,236
- Total Assets
- DKK 591,900
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 436 t. | 371 t. | -1.4 mio. | 1 |
| 2023 | - | -740 t. | -1.5 mio. | -1.7 mio. | 2 |
| 2022 | - | -171 t. | -219 t. | -207 t. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
G2B BioSolutions ApS has published its annual report for 2023. Gross profit came to DKK -739,652, and the net result was DKK -1,513,784.
About G2B BioSolutions ApS
G2B BioSolutions ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Dayanand Suryabhan Jadhav. The company is owned by Dayanand Jadhav Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 44,817 and a net result of DKK 136,864 compared with DKK 370,740 the year before. Equity in the 2025 report amounted to DKK -1,213,372.